Most commonly known psychedelics are considered schedule 1 substances by the controlled substances act, meaning they is no currently accepted medical use and a high potential for abuse. However, there is emerging evidence that psychedelics may have some therapeutic value. Dr. Matthew Johnson discusses the history of psychedelic research in the United States and his work on understanding abuse potential and therapeutic value of one specific psychedelic, psilocybin. Matt is the Susan Hill Ward Professor in Psychedelics and Consciousness and Professor of Psychiatry and Behavioral Sciences at Johns Hopkins.